Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001068641 | SCV001233765 | uncertain significance | Pancreatic adenocarcinoma | 2023-11-06 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 563 of the PALLD protein (p.Leu563Val). This variant is present in population databases (rs200399043, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with PALLD-related conditions. ClinVar contains an entry for this variant (Variation ID: 862010). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV004030683 | SCV003855872 | uncertain significance | not specified | 2023-02-03 | criteria provided, single submitter | clinical testing | The p.L1050V variant (also known as c.3148C>G), located in coding exon 17 of the PALLD gene, results from a C to G substitution at nucleotide position 3148. The leucine at codon 1050 is replaced by valine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |